| Expression pattern: |
UP |
| Associated gene: |
ATG7 |
| Associated microRNA: |
miR-654-5p |
| Biological function: |
Promotes NSCLC cell proliferation, inhibits apoptosis, enhances cisplatin/DDP resistance, promotes autophagy, and is associated with recurrence and poor prognosis. |
| Molecular mechanism: |
hsa_circ_0085131 acts as a ceRNA by sponging miR-654-5p, relieving miR-654-5p-mediated suppression of ATG7 and activating ATG7-dependent autophagy to promote cisplatin resistance. |
| Biological pathway or process: |
autophagy (promotes); drug resistance (promotes); chemoresistance (promotes); proliferation (promotes); apoptosis (inhibits); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; FISH / smFISH; IF (Immunofluorescence); Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Annexin V/PI Flow Cytometry; Western Blot; Cohort Study; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High hsa_circ_0085131 expression predicts recurrence, shorter overall survival, shorter recurrence-free survival, and poor outcome in NSCLC patients. |
| Description: |
hsa_circ_0085131 is a PABPC1-derived circRNA upregulated in NSCLC tumor tissues, recurrent NSCLC tissues, and cisplatin-resistant A549/DDP cells. It promotes proliferation, suppresses apoptosis, enhances cisplatin resistance, and drives autophagy through a hsa_circ_0085131/miR-654-5p/ATG7 axis. Clinically, high hsa_circ_0085131 expression is associated with recurrence and poorer OS and RFS in NSCLC patients. |
| Confidence score: |
0.8859 |